Shots:

• The company has completed the patient recruitment in the P-II MANGROVE trial to evaluate GLPG2737 vs PBO in a ratio (2:1) in 66 patients with ADPKD for 52wks. across 7 countries in the EU. The results are expected in H1’23
• The primary objectives of the trial are to evaluate the effect on the growth of total kidney volume & to assess the overall safety and tolerability @52wks. while secondary objectives include renal function, PK, and PD
• GLPG2737 is a CFTR inhibitor & is indicated to reduce cyst growth and kidney enlargement for patients with ADPKD. Additionally, the therapy was generally well-tolerated in previous clinical trials for patients with the same indication

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Analist